Lapatinib is a dual epidermal growth factor receptor (EGFR)/HER2 inhibitor approved for use in HER2+ BC, while erlotinib and gefitinib target EGFR and are used to treat lung cancer. This evidence concerns the gene EGFR and breast cancer.